154TiP AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)

Pts with LS-SCLC have a modest prognosis (5-year survival rate: 25–30%) and require more effective therapies. T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is a co-inhibitory immune checkpoint receptor upregulated on T-cells and natural killer cells in multiple solid tumors, which can inhibit anticancer immune responses. Dual targeting of tumors with anti-TIGIT and anti-programmed cell death protein 1 (PD-1) produces synergistic immune cell activation and enhanced antitumor activity in preclinical models.